|1.||Lip, Gregory Y H: 6 articles (11/2015 - 07/2011)|
|2.||Lane, Deirdre A: 4 articles (09/2015 - 07/2011)|
|3.||de Boer, Anthonius: 4 articles (04/2014 - 01/2008)|
|4.||Kropacheva, E S: 4 articles (01/2011 - 01/2004)|
|5.||Panchenko, E P: 4 articles (01/2011 - 01/2004)|
|6.||Büller, Harry R: 3 articles (09/2015 - 10/2005)|
|7.||Rosendaal, Frits R: 3 articles (12/2013 - 06/2002)|
|8.||Bykova, E S: 3 articles (01/2007 - 01/2004)|
|9.||Titaeva, E V: 3 articles (01/2007 - 01/2004)|
|10.||Dobrovol'skiĭ, A B: 3 articles (01/2007 - 01/2004)|
|1.||Venous Thrombosis (Deep-Vein Thrombosis)
05/01/1998 - "A 69-year-old man developed cholestatic liver enzyme disturbances three and a half weeks after starting treatment with acenocoumarol because of a deep venous thrombosis in his leg. "
01/01/1998 - "Pharmacokinetic and pharmacodynamic variations of acenocoumarol orally administrated either once or twice daily in patients with deep venous thrombosis."
01/01/1993 - "We present the case of a woman undergoing treatment with acenocoumarol for deep vein thrombosis, who maintained an international normalized ratio (INR) of between 2.5 and 4 for 2 months. "
08/01/2008 - "The patient had been receiving acenocoumarol 4 mg/d for 10 years for episodes of atrial fibrillation and recurrent deep venous thrombosis. "
03/01/2004 - "We present the case of an obese woman that developed an extensive cutaneous necrosis while receiving acenocoumarol for a deep venous thrombosis. "
11/01/2001 - "Even though no clinical benefit (pertaining to the frequency of painful crises) was detected in this pilot study, the value of low adjusted-dose acenocoumarol for preventing specific events (such as strokes) and as a long-term treatment of sickle cell patients should be subject of further study."
01/01/2004 - "Ischemic strokes, episodes of systemic thromboembolism and hemorrhagic complications were registered during 3 years of treatment with acenocoumarol (target INR 2.0-3.0). "
02/25/2014 - "Triflusal plus acenocoumarol is likely more effective than acenocoumarol alone in reducing stroke risk. "
01/01/2015 - "The rates of thromboembolic events were similar under dabigatran and acenocoumarol treatment: strokes, 0.094 vs. 0 /patient-year, p=0.36; systemic embolism, no event in either group; and device thrombosis, 0.053 vs. 0.258 events/patient-year, p=0.19, respectively. "
07/01/2008 - "We report a case of 66-years-old man with prosthetic aortic valve after three ischemic strokes treated with acenocoumarol who was admitted to hospital with vertigo and motoric aphasia. "
01/01/2007 - "The aim of the study was to assess knowledge of oral anticoagulation in a group of patients with atrial fibrillation (AF) treated with acenocoumarol and to determine the relationship between knowledge and INR value. "
11/27/2015 - "To assess effects of the ABCB1 pilymorphisms on safety profile and dosing regimen of acenocoumarol in the patients with valvular atrial fibrillation. "
11/27/2015 - "ABCB1 polymorphism and acenocoumarol safety in patients with valvular atrial fibrillation."
11/01/2015 - "In a prospective "real-world" inception cohort of patients with atrial fibrillation initiating oral anticoagulation with acenocoumarol, we have validated the clinical value of the SAME-TT2R2 score for the identification of patients who would have poor-quality anticoagulation. "
09/01/2015 - "Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation."
02/01/2015 - "Despite the use of high doses of acenocoumarol (114 mg/week) for the treatment of recurrent pulmonary embolism, the International Normalized Ratio was below the therapeutic target. "
01/01/1992 - "Two years after the episode of pulmonary embolism, the patient, still taking acenocoumarol, remained free from any sequela. "
09/01/2000 - "She was treated by acenocoumarol for atrial fibrillation and pulmonary embolism. "
01/01/1994 - "The neutropenia began just after the treatment of pulmonary embolism by acenocoumarol. "
03/01/2007 - "This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism. "
01/01/2004 - "The use of acenocoumarol for 12 months resulted in significant reduction of frequency of left auricular thrombosis. "
12/01/2011 - "There were 2 maternal deaths due to acute mitral valvular thrombosis while on acenocoumarol in the second trimester. "
12/01/2009 - "He was on acenocoumarol treatment because of portal, splenic and mesenteric vein thrombosis (PSMVT) 3 months before, with admission international normalized ratio (INR):1.6. "
01/01/2004 - "Clinical-instrumental predictors of presence of left auricular thrombosis and its dynamics during therapy with acenocoumarol were also elucidated."
10/02/1993 - "[Initial heparinization necessary in patients with thrombosis of the leg; comparison with acenocoumarol treatment]."
|5.||Aspirin (Acetylsalicylic Acid)
|7.||glucuronyl glucosamine glycan sulfate (Vessel)
|9.||Platelet Aggregation Inhibitors (Antiplatelet Drugs)
|2.||Prostheses and Implants (Prosthesis)
|4.||Cesarean Section (Caesarean Section)